Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about the proposed schedule of participation in Investor Conferences by Officials of the Company.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about the proposed schedule of participation in Investor Conferences by Officials of the Company.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about the schedule of meet for Analyst/ Investor Meeting(s) to be held on various dates in August and September 2026.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has published unaudited financial results for the quarter ended June 30, 2026, in newspapers and on their website.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has made the audio recording of its Q1 FY27 earnings call available on its website.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has announced the record date for the final dividend for the financial year ended March 31, 2026, as September 4, 2026. The dividend amount is Rs. 3.60 per equity share, subject to approval at the 45th Annual General Meeting on September 21, 2026.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about change in Management. Mr. Berjis Desai has expressed his unwillingness to seek re-appointment as Chairman and Non-executive, Non-Independent Director, and will cease to hold office from the conclusion of the ensuing AGM. Mr. Raghu Kumar has been appointed as an Additional Director (Non-Executive and Independent) and Mr. Satish Mehta has been appointed as the Chairman of the Company.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation, which includes unaudited financial results for Q1FY27. The presentation highlights a strong all-round performance with increased revenue and growth in the International business (58% contribution). Domestic revenue growth is at 10.2%, with productivity gains and operating leverage improving EBITDA margin by 50 bps and PAT margin by 110 bps. The company has also announced key appointments and restructuring of its leadership and operations.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, and has also made several board-level appointments and changes, including the retirement of Chairman Berjis Desai and the appointment of Satish Mehta as the new Chairman, and the appointment of Raghu Kumar as an Additional Director.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has completed the acquisition of 12.05% of the total issued and paid-up capital of Gennova Biopharmaceuticals Limited, making Gennova a wholly-owned subsidiary of Emcure.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company. Mr. P.S. Jayakumar is completing his 2nd consecutive term as an Independent Director and ceases to be a Director of the Company, with effect from close of business hours on July 21, 2026.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has received CDSCO approval for its co-marketed brand Poviztra for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about the schedule of a meet for Q1 FY27 earnings call, to be held on August 06, 2026.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has consolidated its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, acquiring the entire 12.05% minority stake held by Dr. Sanjay Singh and others, making Gennova a wholly owned subsidiary. Gennova will be led by Mr. Samit Mehta and will focus on its biologics franchise, biosimilars development, and adjacent therapeutic platforms.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has acquired 12.05% stake in its subsidiary Gennova Biopharmaceuticals Limited for Rs. 2,318.7 million.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has submitted a revised intimation of Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, with a correct enclosure.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018. The company has received a Confirmation Certificate from MUFG Intime India Private Limited, the Registrar and Share Transfer Agent (RTA) of the Company, for the quarter ended June 30, 2026.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about the acquisition of Mantra Pharma Inc., a step-down subsidiary of the Company, by Marcan Pharmaceuticals Inc., another subsidiary of the Company, for an aggregate consideration of CAD $50 million.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about change in Management, with Mr. Kuber Jagdale, President – API Business, superannuating from his employment with the Company with effect from close of business hours on June 30, 2026.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange regarding the closure of the trading window for its designated persons and their immediate relatives due to the declaration of unaudited financial results for the quarter ending June 30, 2026.